Sequence: RKKRRQRRRGGGKLLKLLLKLLLKLLK-CONH2
| Experiment Id | EXP001866 |
|---|---|
| Paper | Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting bcr–abl fusion gene in Chron |
| Peptide | Tat–LK15 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | Example prep (1:1 charge ratio): 0.81 µg peptide in 50 µL HEPES-buffered saline mixed with 1 µg oligo in 50 µL; incubate 30 min RT. Higher charge ratios used for functional assays. |
| Rna Concentration | siRNA 1–30 µg (≈60 nM–1.8 µM range) tested; key readout at 48 h post-transfection |
| Mixing Ratio | (+/−) charge ratio 3:1 (Tat–LK15:siRNA) for silencing studies |
| Formulation Format | Noncovalent electrostatic peptide/nucleic acid complexes |
| Formulation Components | Tat–LK15 fusion peptide complexed with BCR–ABL-targeting siRNA or shRNA expression plasmid (pSilencer 2.0 U6 hygro) |
| Size Nm | 663.40 |
| Zeta Mv | 10.55 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | K562 human chronic myelogenous leukemia cells |
| Animal Model | |
| Administration Route | |
| Output Type | Gene silencing (BCR–ABL protein by Western blot at 48 h) |
| Output Value | ≥~70% BCR–ABL protein reduction at 48 h across wide siRNA amounts (max around 5–10 µg); silencing not observed beyond 48 h (transient) |
| Output Units | |
| Output Notes | Cy5-siRNA uptake by FACS up to ~60% positive cells; higher charge ratio associated with higher toxicity vs shRNA complexes. |
| Toxicity Notes | MTT: siRNA complexes significantly more toxic than shRNA complexes at 24 h; Tat–LK15 alone high toxicity at higher concentrations. |
| Curation Notes |